嬰兒受益益生元,表明研究

五歲以下兒童的團體之一容易腸胃感染,特別是當他們開始參加日托中心。監管和營養支持經理Wim Caers Orafti告訴NutraIngredients.com說,有越來越多的興趣在嬰兒和後續公式使用生命起源以前的成分,大西洋兩岸的。“如果你比較母乳喂養和標準配方奶喂養的寶寶的健康,標準瓶喂嬰兒更容易受到便秘,”他說。研究人員發現,母乳中含有低聚糖,認為刺激雙歧杆菌——即所謂的“友好”的細菌幫助從食物中釋放能量和營養。Caers表示,大多數公式使用益生元目前正在開發,但是趨勢已經被推出一個初始的幾個沉澱。在新投稿的獨立研究,學院的教授比泰爾製藥的影響評估Orafti的Raftilose P95 oligofructose成分在一群35嬰兒年齡在6 - 24個月,在巴黎參加一個日托中心,法國。沒有孩子們收到了抗生素研究的開始之前,他們也沒有被母乳喂養的前30天。他們被隨機分配到兩個組,一個接收2 g的Raftilose P95每天消費的食品和飲料,另一個接受安慰劑(麥芽糊精)。在第一周的為期六周的研究中,嬰兒隻是觀察。補充第二周開始,持續兩周,之後還有另一個,並且觀察。 In addition to assessing questionnaires completed by care-givers as to gastrointestinal symptoms and general health, Butel collected stools for bacteriological analysis after the initial observation period and at the start and end of each of the following periods. On analysis, she found that the composition of the colonic flora was beneficially modulated in the oligofructose group compared to the placebo group: After three weeks, they had an increase of 9.5 log cfu (colony forming units) of bifidobacteria per gram of faeces. The increase was greatest in those infants whose colonisation levels were lowest at the start of the trial. Numbers of clostridia (thought to be bacterial pathogens) were also decreased after three weeks of supplementation. Moreover, the oligofructose appeared to have a positive effect on the infants' overall well-being, lowering the number of febrile events and symptoms of gastrointestinal illness, such as flatulence, diarrhoea and vomiting. Raftilose P95 is contained in more than 2,500 food products throughout the world, mostly staples such as breads, cereals and yoghurts. But foods designed specifically for infants are a relatively new application. Orafti is also participating in a recently-started project funded by the European Commission, which aims to investigate the importance of early nutrition in reducing the risk of adult diseases. This project will study the effects of a prebiotic formula containing both inulin and oligofructose, particularly on the immune system and in infants at high risk of developing allergies. External links to companies or organisations mentioned in thisstory: Orafti